Online inquiry

IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ500MR)

This product GTTS-WQ500MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Urticaria research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ500MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7128MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ9397MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ13573MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ8359MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ14204MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ3151MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ1301MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ400MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW